Tigecycline Resistance Trends Worldwide
Tigecycline, a glycylcycline antibiotic used against multidrug-resistant bacteria, shows rising resistance in multiple regions. Global surveillance data from 2010-2023 indicates minimum inhibitory concentration (MIC) creep, where bacteria require higher drug doses to be inhibited. Resistance rates exceed 20% in some Gram-negative pathogens like Acinetobacter baumannii and Klebsiella pneumoniae in high-burden areas.[1][2]
Which Locations Report Highest Increases?
- China: Resistance in A. baumannii climbed from 5-10% in 2010 to 30-50% by 2022, linked to heavy hospital use and carbapenemase producers. Studies from Beijing and Shanghai hospitals show tet(X) genes driving plasmid-mediated resistance.[3][4]
- India: Rates in Enterobacteriaceae reached 25-40% in ICU settings by 2021, with MIC90 values doubling since 2015. Urban centers like Delhi and Mumbai report the sharpest rises.[5]
- Middle East (e.g., Saudi Arabia, UAE): A. baumannii resistance hit 40-60% in 2020-2023 surveillance, tied to regional conflict and overuse.[6]
- Europe and US: Lower but growing—10-20% in K. pneumoniae in southern Europe (Greece, Italy); US rates stable at 5-15% but rising in long-term care facilities.[7][8]
Asia dominates increases, with 2-5x rises over a decade versus slower growth elsewhere.
Why Is Resistance Rising in These Spots?
Overuse in ICUs for carbapenem-resistant infections, combined with mobile tet(X3-X7) genes on plasmids, accelerates spread. Poor infection control and travel from high-prevalence areas contribute. Unlike older tetracyclines, tigecycline's efflux pump resistance via tet genes is a key mechanism.[9]
What Happens in Low-Resistance Areas?
Scandinavia and Canada maintain <5% rates through stewardship programs limiting tigecycline to last-resort cases. However, imported cases from Asia signal potential spillover.[10]
Testing and Clinical Implications
Labs use EUCAST or CLSI breakpoints; rising MICs (e.g., >2 mg/L) predict failures. Physicians in high-resistance zones shift to combinations like tigecycline-eravacycline or new agents like plazomicin.[11]
Surveillance Data Sources
[1] Tigecycline resistance worldwide: a systematic review (2023), Journal of Antimicrobial Chemotherapy
[2] SENTRY Antimicrobial Surveillance (2018-2021), Clinical Infectious Diseases
[3] Tet(X)-mediated tigecycline resistance in China, Lancet Infectious Diseases (2022)
[4] Chinese SMART surveillance, Antimicrobial Agents and Chemotherapy (2023)
[5] INFORM India study (2021), Journal of Global Antimicrobial Resistance
[6] Middle East tigecycline study, International Journal of Infectious Diseases (2022)
[7] European tigecycline report, Eurosurveillance (2023)
[8] CDC US data, Emerging Infectious Diseases (2023)
[9] Mechanisms review, mBio (2022)
[10] Nordic surveillance, APMIS (2023)
[11] IDSA guidelines update (2023)